Fukui S, Sumiyoshi R, Koga T, Hosogaya N, Narita S, Morimoto S
Cureus. 2025; 17(2):e78974.
PMID: 39958406
PMC: 11826103.
DOI: 10.7759/cureus.78974.
Kakutani T, Kamada R, Tamai Y
Curr Issues Mol Biol. 2024; 46(10):11255-11269.
PMID: 39451548
PMC: 11506032.
DOI: 10.3390/cimb46100668.
Smith D, Eichinger A, Rech A, Wang J, Esteva E, Seyedian A
bioRxiv. 2024; .
PMID: 39314418
PMC: 11419132.
DOI: 10.1101/2024.09.09.609717.
Bi X, Huang R, Ming C, Lou F, Xie Y, Yang H
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2024; 38(8):732-736.
PMID: 39118513
PMC: 11612750.
DOI: 10.13201/j.issn.2096-7993.2024.08.011.
Sumiyoshi R, Koga T, Kawakami A
Biomedicines. 2024; 12(6).
PMID: 38927348
PMC: 11200392.
DOI: 10.3390/biomedicines12061141.
Unmet Clinical Needs in the Management of Idiopathic Multicentric Castleman Disease: A Consensus-based Position Paper From an ad hoc Expert Panel.
Zinzani P, Paulli M, Arcaini L, Della Torre E, Ferrero S, Figuera A
Hemasphere. 2023; 7(6):e891.
PMID: 37234822
PMC: 10208718.
DOI: 10.1097/HS9.0000000000000891.
Candidate biomarkers for idiopathic multicentric Castleman disease.
Sumiyoshi R, Koga T, Kawakami A
J Clin Exp Hematop. 2022; 62(2):85-90.
PMID: 35768241
PMC: 9353853.
DOI: 10.3960/jslrt.22010.
Castleman disease.
Carbone A, Borok M, Damania B, Gloghini A, Polizzotto M, Jayanthan R
Nat Rev Dis Primers. 2021; 7(1):84.
PMID: 34824298
PMC: 9584164.
DOI: 10.1038/s41572-021-00317-7.
Transcriptome and unique cytokine microenvironment of Castleman disease.
Wing A, Xu J, Meng W, Rosenfeld A, Li E, Wertheim G
Mod Pathol. 2021; 35(4):451-461.
PMID: 34686774
PMC: 9272352.
DOI: 10.1038/s41379-021-00950-3.
Histologic and Laboratory Characteristics of Symptomatic and Asymptomatic Castleman Disease in the Pediatric Population.
Chisholm K, Fleming M
Am J Clin Pathol. 2020; 153(6):821-832.
PMID: 32112075
PMC: 7453143.
DOI: 10.1093/ajcp/aqaa011.
Castleman's disease combined with choledocholithiasis: a case report and review of literature.
Jiang Z, Feng S, Liu G, Chen M, Sun J
Int J Clin Exp Pathol. 2020; 11(11):5491-5496.
PMID: 31949635
PMC: 6963044.
A rare case of renal thrombotic microangiopathy associated with Castleman's disease.
Mutneja A, Cossey L, Liapis H, Chen Y
BMC Nephrol. 2017; 18(1):57.
PMID: 28183278
PMC: 5301347.
DOI: 10.1186/s12882-017-0472-2.
Dendritic cell-derived VEGF-A plays a role in inflammatory angiogenesis of human secondary lymphoid organs and is driven by the coordinated activation of multiple transcription factors.
Salvi V, Vermi W, Gianello V, Lonardi S, Gagliostro V, Naldini A
Oncotarget. 2016; 7(26):39256-39269.
PMID: 27256980
PMC: 5129930.
DOI: 10.18632/oncotarget.9684.
Idiopathic multicentric Castleman's disease: a systematic literature review.
Liu A, Nabel C, Finkelman B, Ruth J, Kurzrock R, van Rhee F
Lancet Haematol. 2016; 3(4):e163-75.
PMID: 27063975
DOI: 10.1016/S2352-3026(16)00006-5.
Next-Generation Sequencing in the Understanding of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Biology.
Strahan R, Uppal T, Verma S
Viruses. 2016; 8(4):92.
PMID: 27043613
PMC: 4848587.
DOI: 10.3390/v8040092.
Castleman Disease. A Report of Six Cases.
Fetica B, Pop B, Lisencu C, Rancea A, Coman A, Cucuianu A
Clujul Med. 2015; 87(3):192-7.
PMID: 26528023
PMC: 4508595.
DOI: 10.15386/cjmed-302.
Pelvic Castleman's disease presenting as an adnexal tumor in a young woman.
Lee J, Paek J, Lee Y, Kong T, Chang S, Ryu H
Obstet Gynecol Sci. 2015; 58(4):323-6.
PMID: 26217605
PMC: 4515484.
DOI: 10.5468/ogs.2015.58.4.323.
Chromatinization of the KSHV Genome During the KSHV Life Cycle.
Uppal T, Jha H, Verma S, Robertson E
Cancers (Basel). 2015; 7(1):112-42.
PMID: 25594667
PMC: 4381254.
DOI: 10.3390/cancers7010112.
KSHV: pathways to tumorigenesis and persistent infection.
Giffin L, Damania B
Adv Virus Res. 2013; 88:111-59.
PMID: 24373311
PMC: 4104069.
DOI: 10.1016/B978-0-12-800098-4.00002-7.
Castleman disease.
Saeed-Abdul-Rahman I, Al-Amri A
Korean J Hematol. 2012; 47(3):163-77.
PMID: 23071471
PMC: 3464333.
DOI: 10.5045/kjh.2012.47.3.163.